The search for new triazole antifungal agents

被引：101

作者：

Koltin, Y

Hitchcock, CA

机构：

[1] Millennium Pharmaceut Inc, Div Mol & Cellular Biol, Cambridge, MA 02139 USA

[2] Pfizer Ltd, Cent Res, Dept Discovery Biol, Sandwich CT13 9NJ, Kent, England

来源：

CURRENT OPINION IN CHEMICAL BIOLOGY | 1997年 / 1卷 / 02期

关键词：

D O I：

10.1016/S1367-5931(97)80007-5

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The first generation antifungal agent triazoles, fluconazole and itraconazole, have revolutionised the treatment of serious fungal infections such as mucosal and invasive candidiasis and cryptococcal meningitis. However, the treatment of some fungal infections, particularly aspergillosis, is still far from satisfactory and thus there is an important requirement for new broad-spectrum antifungal agents. The new second generation triazoles voriconazole and SCH-56592 show considerable promise in achieving this goal in the near future. (C) Current Biology Ltd ISSN 1367-5931.

引用

页码：176 / 182

页数：7

共 51 条

[1] Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: A matched cohort study [J].